Bicycle Therapeutics
Cambridge
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $1.1B
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2024)
- Ticker: nasdaq:BCYC
- Website: bicycletherapeutics.com
- Phone: +44 1223 497 415
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bicycle-therapeutics-29519 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.